Vision Equipment-600X120-Above Article-Equipment Source

“You just can’t take the effect, and make it the cause…..” The White Stripes

Talk about a hot topic! Without much controversy on the OD side, our efforts at myopia control are gaining steam. The science is really cooking, and clinical enthusiasm is growing by leaps and bounds. Old ideas like “undercorrecting” and bifocal glasses for kids are going out. Orthokeratology, atropine, and multifocal soft lenses all seem to play major roles in this potentially life-changing treatment. It works, folks, and is likely to get better.

But, I’m worried about this………..

Sometimes, when a field is fresh and new, the enthusiasm can take us a step ahead of ourselves. Myopia control is apparently no exception, with some practitioners making claims that I can only describe as alarming. I’m referring to colleagues who are advising patients that myopia control reduces the chances of The Big Three associated pathologies, namely, retinal detachment, cataract, and glaucoma. I admit that I was shocked when I first heard these suggestions.

If you would like to read this complete article, please log in to become a member!

You do not have access to this post.

Bill Potter
Associate Editor, Dugout Dirt Editorial for Dr. Bill Potter is the senior optometrist at Millennium Eye Care in Freehold, New Jersey. Millennium is a multi-subspecialty optometry/ophthalmology practice, where Bill has practiced for 31 years. Prior to this, he served for 3 years as a Captain and optometrist in the U.S. Air Force. Bill is a graduate of the University of Pennsylvania and the Pennsylvania College of Optometry. He serves as a member of the Review of Optometry’s Editorial Board. The Primary Care Optometry News honored Dr. Potter in 2016 by listing him as one of the “PCON 250” top leaders and innovators in his field. Dr. Potter has a special interest in uveitis and other ocular inflammatory diseases and has lectured and published many articles in this area. Most recently, Bill’s CE article on “Red Disease in Glaucoma” appeared in the March 2017 Review of Optometry.